Development and Validation of DDP-4 inhibitors and prognosis of COVID‐19

DDP-4 inhibitor

Development and Validation of DDP-4 inhibitors and prognosis of COVID‐19

DDP-4 inhibitor

Day: May 1, 2026

In unadjusted models, we observed a statistically significant association with hepatic decompensation for age, year at entry, race, diabetes, HBV, HCV therapy, FIB-4 score, alcohol abuse, AIDS-defining conditions, CD4 count, and HIV RNA (Table1)

by asiatox May 1, 2026 4 Min Reading

In unadjusted models, we observed a statistically significant association with hepatic decompensation for age, year at entry, race, diabetes, HBV, HCV therapy, FIB-4 score, alcohol

Day: May 1, 2026

﻿In unadjusted models, we observed a statistically significant association with hepatic decompensation for age, year at entry, race, diabetes, HBV, HCV therapy, FIB-4 score, alcohol abuse, AIDS-defining conditions, CD4 count, and HIV RNA (Table1)

In unadjusted models, we observed a statistically significant association with hepatic decompensation for age, year at entry, race, diabetes, HBV, HCV therapy, FIB-4 score, alcohol abuse, AIDS-defining conditions, CD4 count, and HIV RNA (Table1)